Key regions: Australia, Italy, France, South Korea, Brazil
The demand for vaccines in Burkina Faso has been on the rise in recent years.
Customer preferences: Burkina Faso has a young population, with about two-thirds of its citizens under the age of 25. This demographic trend has led to a growing demand for vaccines, especially for children. The government has prioritized immunization as a key public health strategy, with a focus on preventing diseases such as measles, polio, and yellow fever.
Trends in the market: The vaccines market in Burkina Faso is dominated by multinational pharmaceutical companies, which supply the majority of vaccines used in the country. There has been a trend towards greater availability of vaccines in rural areas, where access to healthcare services is limited. The government has also been working to increase vaccination coverage rates, with a particular focus on reaching marginalized populations such as nomadic communities.
Local special circumstances: Burkina Faso is one of the poorest countries in the world, with a low GDP per capita and limited healthcare resources. This has led to challenges in ensuring an adequate supply of vaccines, as well as in providing healthcare services more broadly. However, the government has made progress in recent years in improving access to vaccines, with support from international organizations such as the World Health Organization and UNICEF.
Underlying macroeconomic factors: The vaccines market in Burkina Faso is influenced by a range of macroeconomic factors, including government spending on healthcare, foreign aid, and the availability of skilled healthcare workers. The government has made efforts to increase healthcare spending in recent years, but this remains a challenge given the country's limited resources. Foreign aid has played an important role in supporting vaccination programs, but there are concerns about the sustainability of these programs over the long term. Finally, the shortage of skilled healthcare workers in Burkina Faso is a major challenge, as this limits the capacity of the healthcare system to deliver vaccines and other healthcare services.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
